FAIRFIELD, Conn., Jan. 15, 2014 /PRNewswire/ -- Competitive
Technologies, Inc., (OTCQX: CTTC) (CTI), a biotechnology
company, received a favorable Medicare treatment coverage judgment
for its flagship medical technology device, the Calmare®
pain therapy medical device, stemming from an appeal filed by an
authorized Calmare practitioner in Staten
Island, the Physical Medicine and Rehabilitation Associates
of Staten Island, LLP (collectively,
the Calmare Pain Relief Solutions or CPRS), by and through,
Christopher M. Perez, M.D. U.S.
Administrative Law Judge LeAnn R.
Canter allowed the appeal, which resolved claims for
Medicare coverage for a named Medicare enrollee (Beneficiary). The
appeal allows CPRS to receive reimbursements for treatments using
the Calmare Therapy for claims made in behalf of beneficiary.
In the early part of 2011, CPRS was denied Medicare payments for
treatments rendered to a Beneficiary who was 69 years old, at the
time of the treatment. The Beneficiary had a medical history of
breast cancer, for which she had undergone mastectomy and
chemotherapy treatments. She had pain from the cancer-related
chemotherapy treatments that had an intensity level of 7 on a scale
of 10, and a pain recurrence of 75% of the time.
The Calmare treatment was denied reimbursement coverage mostly
due to the lack of inclusion of a Current Procedural Terminology
(CPT) treatment code descriptor that would apply to the treatment
type inherent to Calmare pain treatment therapy. CPRS filed an
appeal (ALJ Appeal No 1-1009277156) to the Department of Human
Services Office of Medicare Hearings and Appeals Midwestern Field
Office in Cleveland, OH.
Judge Canter's ruling established that there was reliable
evidence and sufficient documentation of the Beneficiary's medical
conditions to establish the medical necessity of the Calmare
Therapy treatments. In turn, the medical records and the hearing
testimony supplied ample evidence that the treatments at issue
greatly improved the Beneficiary's pain management over the brief
course of treatment.
"This ruling will help broaden Calmare's patient reach and
treatment efficacy," commented CTI President & CEO Conrad Mir. "Treatment reimbursement has been a
challenge to the furtherance of Calmare. With this significant
business milestone achieved, we anticipate greater treatment
reimbursements moving forward, which may improve device sales to
physicians."
About Calmare Pain Relief Solutions (CPRS)
Calmare
Pain Relief Solutions is a Physician group which specializes in
offering a non-narcotic and non-invasive solution for chronic pain.
Christopher Perez, MD and
Jack D'Angelo, MD, specialize in
physical medicine and rehabilitation and together have over 30
years of clinical experience treating chronic neuropathic pain.
About CPRS Physicians
The physicians at Calmare Pain
Relief Solutions, Christopher Perez,
MD and Jack D'Angelo, MD, have been
treating chronic pain patients suffering from neuropathies such as
failed back surgery, Reflex Sympathetic Dystrophy (RSD/CRPS), and
Chemotherapy-induced Peripheral Neuropathy (CIPN) since 2010.
About the Company
Competitive Technologies Inc., is a
biotechnology company developing and commercializing innovative
wound and pain mitigation products and technologies. CTI is the
licensed distributor of the non-invasive Calmare® pain
therapy medical device, which incorporates the biophysical
"Scrambler Therapy"® technology developed to treat
neuropathic and cancer-derived pain by Professor Giuseppe Marineo.
Forward-Looking Statements
Certain statements
contained in this press release are forward-looking statements that
involve risks and uncertainties. The statements contained herein
that are not purely historical are forward looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements deal with the Company's current
plans, intentions, beliefs and expectations and statements of
future economic performance. Forward-looking statements
involve known and unknown risks and uncertainties that may cause
the Company's actual results in future periods to differ materially
from what is currently anticipated. Factors that could cause or
contribute to such differences include those discussed from time to
time in reports filed by the Company with the Securities and
Exchange Commission. The Company cannot guarantee its future
results, levels of activity, performance or achievements.
Contacts:
|
|
Competitive Technologies,
Inc.
|
JV Public Relations
|
Conrad
Mir
|
Janet Vasquez
|
President and
CEO
|
Managing Director
|
cmir@competitivetech.net
|
jvasquez@jvprny.com
|
973.798.8882
|
212.645.5498
|
Scrambler Therapy®:
www.scramblertherapy.org/english.htm
Calmare®: www.calmarett.com
www.competitivetech.net
SOURCE Competitive Technologies, Inc.